Allianz Asset Management GmbH Purchases New Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Allianz Asset Management GmbH purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,600 shares of the company’s stock, valued at approximately $227,000.

Other large investors have also recently bought and sold shares of the company. Amalgamated Bank lifted its position in shares of Tarsus Pharmaceuticals by 30.1% in the first quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock valued at $65,000 after buying an additional 295 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Tarsus Pharmaceuticals by 26.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock worth $66,000 after purchasing an additional 339 shares during the period. Quarry LP increased its stake in shares of Tarsus Pharmaceuticals by 20.0% during the first quarter. Quarry LP now owns 3,599 shares of the company’s stock worth $185,000 after purchasing an additional 599 shares during the period. AlphaQuest LLC bought a new position in Tarsus Pharmaceuticals during the 1st quarter worth $189,000. Finally, FORA Capital LLC bought a new position in Tarsus Pharmaceuticals during the 1st quarter worth $271,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total value of $332,220.00. Following the transaction, the chief executive officer owned 812,106 shares in the company, valued at $44,966,309.22. The trade was a 0.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William J. Phd Link sold 27,116 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the transaction, the director owned 143,332 shares in the company, valued at $8,169,924. The trade was a 15.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 39,116 shares of company stock valued at $2,177,832 over the last three months. Corporate insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 0.9%

Shares of TARS opened at $67.56 on Wednesday. The company has a market capitalization of $2.85 billion, a PE ratio of -29.00 and a beta of 0.81. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $76.81. The stock’s 50-day moving average price is $60.93 and its two-hundred day moving average price is $50.12. The company has a current ratio of 5.26, a quick ratio of 5.21 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.The business had revenue of $102.66 million during the quarter, compared to the consensus estimate of $95.81 million. On average, analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TARS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright raised their price objective on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research note on Monday, October 20th. Finally, Zacks Research upgraded Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $69.33.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.